Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 dose-finding study of anti-TSLP antibody GSK5784283 in adults with uncontrolled asthma
jRCT2051240295Phase 2Recruiting
- Sponsor
- GSK
- Start
- May 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing GSK5784283 dose groups with Placebo (2 arms). Primary endpoint: Change from baseline in the fraction of exhaled nitric oxide (FeNO). Started May 2025; status: recruiting.
02
Drugs
SHR-1905
03
Conditions
asthma
Beyond the preview
Go deeper on jRCT2051240295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240295.